

Bacillus Calmette-Guerin vaccine may reduce atopic dermatitis

September 25 2017



(HealthDay)—Bacillus Calmette-Guérin (BCG) vaccination within seven

days of birth may reduce the risk of allergic diseases, including atopic dermatitis, according to a study published online Sept. 20 in *Allergy*.

Lisbeth Marianne Thøstesen, M.D., Ph.D., from Kolding Hospital in Denmark, and colleagues randomized newborns within seven days of birth to BCG or no BCG as part of the Danish Calmette Study (2012 to 2015). Over 13 months of follow-up, data were collected through telephone interviews and clinical examinations.

The researchers found that clinical atopic dermatitis was diagnosed in 466 of 2,052 children in the BCG group and 495 of 1,952 children in the control group (relative risk, 0.90; 95 percent confidence interval, 0.80 to 1.00). There was a significant difference in the effect of neonatal BCG vaccination between children with atopic predisposition (relative risk, 0.84; 95 percent confidence interval, 0.74 to 0.95) and children without atopic predisposition (relative risk, 1.09; 95 percent confidence interval, 0.88 to 1.37) (test of no interaction, $P = 0.04$).

"Among [children](#) with [atopic](#) predisposition, the number-needed-to-treat with BCG to prevent one case of [atopic dermatitis](#) was 21," the authors write.

More information: [Abstract](#)

[Full Text \(subscription or payment may be required\)](#)

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: Bacillus Calmette-Guerin vaccine may reduce atopic dermatitis (2017, September 25) retrieved 12 September 2024 from <https://medicalxpress.com/news/2017-09-bacillus-calmette-guerin-vaccine-atopic-dermatitis.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.